Search

Your search keyword '"Mielgo-Rubio X"' showing total 4 results
Start Over Author "Mielgo-Rubio X" Topic immunotherapy
4 results on '"Mielgo-Rubio X"'

1. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

Author

Garde-Noguera, J., Martin-Martorell, P., De Julián, M., Perez-Altozano, J., Salvador-Coloma, C., García-Sanchez, J., Insa-Molla, A., Martín, M., Mielgo-Rubio, X., Marin-Liebana, S., Blasco-Cordellat, A., Blasco-Molla, S., Gironés, R., Marquez-Medina, D., Aparisi, F., Cerda, M. C. Bas, Macia-Escalante, S., Sánchez, A., and Juan-Vidal, O.

Published
2018
Full Text
View/download PDF

2. Immunotherapy moves to the early-stage setting in non-small cell lung cancer: emerging evidence and the role of biomarkers

Author

Mielgo-Rubio, X. (Xabier)

Subjects
Immunotherapy, Early-stage, Non-small cell lung cancer, Biomarkers, PD-1, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab
Abstract

Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis blocking-based immunotherapy, have significantly improved survival in advanced non-small cell lung cancer (NSCLC) and both therapies are now well-established in this clinical setting. However, it is time for immunotherapy to be applied in patients with early-stage disease, which would be an important qualitative leap in the treatment of lung cancer patients with curative intent. Preliminary data from a multitude of studies are highly promising, but therapeutic decision-making should be guided by an understanding of the molecular features of the tumour and host. In the present review, we discuss the most recently published studies and ongoing clinical trials, controversies, future challenges and the role of biomarkers in the selection of best therapeutic options.

Published
2018

3. 1376P Early detection of disease progression in NSCLC patients undergoing immunotherapy through ctDNA analysis.

Author

Calvo de Juan, V., Robado de Lope, L., Collazo Lorduy, A., Blanco Clemente, M., Peña Cabia, S., Sequero Lopez, S., Massuti Sureda, B., Diz Tain, P., Vazquez Estevez, S., Mielgo Rubio, X., Oramas Rodriguez, J.M., Sala Gonzalez, M.A., Lopez Martin, A., Rogado, J., Sanchez Hernandez, A., Coves Sarto, J., Gonzalez-Larriba, J.L., Martinez De Castro, A.M., Romero, A., and Provencio Pulla, M.

Subjects
*EARLY diagnosis, *CIRCULATING tumor DNA, *DISEASE progression, *IMMUNOTHERAPY, *NON-small-cell lung carcinoma
Published
2024
Full Text
View/download PDF

4. 1809P Validation of the lung inmune prognostic (LIPI) index in first-line immunotherapy treatment of small cell lung carcinoma.

Author

Cruz Castellanos, P., Gutierrez Sainz, L., Fernandez Franco, L., Rogado, J., Mielgo Rubio, X., Collazo Lorduy, A., Riesco Montes, B., Traseira Puchol, C., Simon, S., Falagán Martínez, S., Chara Velarde, L.E., Martin Fernandez, A.M., Cabezon Gutierrez, L., Lopez Martin, A., Sanchez Sanchez, J.L., Cerezo Gonzalez, S., Viana, A., and Muñoz-Rodriguez, J.R.

Subjects
*SMALL cell carcinoma, *IMMUNOTHERAPY
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results